In a typical IQVIA first-round case, I stop listening when the candidate multiplies "patients with the disease" by list price and calls it a market. Prevalence is epidemiology. Revenue is treated patients times net price after rebates, covered by a payer who may refuse the drug entirely. That is the filter.
IQVIA is not a generalist firm with a healthcare costume. Per its 2025 results release, the company reported $16.31 billion in full-year 2025 revenue. Its About page describes roughly 93,000 employees across more than 100 countries, pairing clinical research, commercial insights, and healthcare intelligence. The consulting work that sits next to that data business is launch, pricing, market access, and commercial analytics for pharma and biotech. The interview mirrors the job.
After this piece you should be able to drive a candidate-led life-sciences case, request the right data in the right order, and land a recommendation a commercial lead would act on. CoachNed is not affiliated with IQVIA.
What the firm actually sells (and why that shows up in the case)
IQVIA's own filings describe analytics and consulting that help life-sciences clients with R&D strategy, portfolio and brand strategy, pricing and market access, and launch excellence. A current Market Access Strategy Consulting associate posting is blunt about the problem: insurers restrict access to therapies that carry less value for them, so manufacturers need strategies for contracting, affordability programs, and net revenue. That sentence is a better prep cue than any memorized framework.
When an interviewer hands you a launch or pricing prompt, they are listening for whether you treat the commercial system as the decision environment. Science background helps. It is not required. What is required is comfort converting clinical and epidemiologic inputs into a business recommendation under uncertainty.
Candidate-led mechanics: silence is your cue
IQVIA cases are candidate-led in the same family as BCG or Bain live cases: you structure, you choose the branch, you ask for data, you synthesize without being prompted. The interviewer answers questions. They do not feed the next exhibit on a timer.
A scoring heuristic I use when I sit on this side of the table:
| Signal | Pass | Leak |
|---|---|---|
| Opening | Restates the decision and constraints in one sentence | Restates the prompt and waits |
| Structure | MECE branches tailored to patients, access, competition, economics | Generic profitability 2x2 |
| Data asks | Specific ("eligible patients on second-line therapy?") | Vague ("any data on the market?") |
| Math | States assumptions, tracks units, distinguishes list vs net | Blends prevalence with revenue |
| Close | Recommendation, risk, next Monday step | Summary of analysis without a call |
If you have only practiced interviewer-led McKinsey-style cases, drill the habit of asking. Thirty seconds of silence after your structure is not awkward. It is your move.
The four numbers that decide most IQVIA cases
You do not need a medical degree. You do need the commercial equation the FDA path does not give you. The FDA drug development overview walks discovery through post-market monitoring; clinical research phases are defined further in FDA clinical research guidance (Phase 1 roughly 20–80 subjects for safety; Phase 2 up to a few hundred for early efficacy; Phase 3 hundreds to thousands for pivotal benefit-risk). Approval is the gate to legal sale. It is not the gate to paid use.
Walk into the room owning these four:
- Eligible patients — prevalence or incidence filtered by label, severity, prior therapy, and diagnosis rates.
- Treated patients — eligible times diagnosis rate times treatment rate times share.
- Net price — list price minus rebates, channel fees, and patient assistance; gross-to-net can cut a large share of list.
- Economics — COGS, sales and medical spend, and remaining exclusivity years.
Ned's rule. Never quote a market as prevalence times list price. Ask for net price and covered lives first. If the interviewer will not give net price, state a gross-to-net haircut as an assumption and keep going.
That rule alone separates candidates who sound like consultants from candidates who sound like they read a Wikipedia page on diabetes.
A worked go/no-go: HelixPeak's second-line oral for chronic itch
Invented company, invented numbers. Reproduce the arithmetic yourself.
Prompt. HelixPeak Biotech has completed Phase 3 for Oracalm, an oral therapy for moderate-to-severe chronic idiopathic pruritus in adults who failed first-line topical steroids. Management wants a launch recommendation for the US. You have 25 minutes. Drive.
Clarify. Decision is US launch now versus delay or partner. Objective is five-year contribution margin, not vanity peak sales. Constraints: one competitor on market; payers will demand outcomes data; manufacturing is contract-filled.
Structure (state it, then pick a branch). Addressable patients → access and net price → competitive share → unit economics and five-year cash → risks and alternatives.
Data you request (and what I would give as interviewer).
| Ask | Answer |
|---|---|
| US adults with moderate-severe chronic idiopathic pruritus | 4.0 million |
| Diagnosed and under dermatologist care | 35% |
| Failed first-line topicals (label-eligible) | 40% of diagnosed |
| Expected peak share among treated eligibles | 18% by year 3 |
| List price per patient-year | $28,000 |
| Expected gross-to-net | 45% |
| Variable COGS per patient-year | $2,200 |
| Launch-year commercial and medical spend | $180 million, then $90 million / year |
| Peak uptake year | Year 3; years 1–2 at 40% and 70% of peak treated |
Eligible and treated at peak.
- Diagnosed: 4.0m × 0.35 = 1.4m
- Label-eligible: 1.4m × 0.40 = 560,000
- Peak treated on Oracalm: 560,000 × 0.18 = 100,800 patients
Net revenue at peak.
- Net price: $28,000 × (1 − 0.45) = $15,400
- Peak net revenue: 100,800 × $15,400 ≈ $1.55 billion
Contribution before fixed commercial spend at peak.
- Variable margin per patient: $15,400 − $2,200 = $13,200
- Peak variable contribution: 100,800 × $13,200 ≈ $1.33 billion
- After $90m run-rate commercial: roughly $1.24 billion
Five-year rough cut (treated ramp 40% / 70% / 100% / 100% / 90% of peak; commercial $180 / $90 / $90 / $80 / $70m). Variable contribution across five years is on the order of $4.5–4.7 billion before commercial spend of about $510 million. Even if share lands at 12% instead of 18%, the launch still clears a sensible bar unless access collapses.
Recommendation. Launch. The economics work at realistic share if payers cover at the assumed net. Lead with a risk: if commercial plans cover only 50% of eligibles at preferred status, treated patients and revenue halve. Next Monday step: model two payer scenarios (broad preferred vs restricted specialty) before locking sales-force size.
Notice what you did not do: you did not open with "profitability, growth, risk" as three empty buckets. You built a patient funnel, forced net price into the math, and closed with a conditional call.
Process shape: what is firm-stated vs recruiting folklore
IQVIA does not publish a single public playbook for every consulting interview. Job postings describe the work; they rarely describe the room. Across recruiting cycles, candidates commonly report a short phone screen, a first round that mixes a candidate-led case with behavioral questions, and a final round with deeper cases and often a written case or short deck. Exact lengths and counts vary by office, school channel, and team (Advisory, Market Access, Analytics). Treat invitation emails as the source of truth for your process.
What does not vary much: you will be asked why healthcare and why IQVIA's data-plus-consulting model, and you will be expected to drive at least one commercial life-sciences case without waiting for slides.
For the written piece, lead with the recommendation on slide one. Supporting slides cover demand math, access and economics, risks, and next steps. Fancy design does not score. A client-readable decision does.
Behavioral and "why IQVIA" without the brochure voice
Fit interviews here punish generic consulting romance. Connect to a concrete reason you want commercial life sciences: a project, a patient pathway problem, or analytic work you have already done. Prepare five short stories (under two minutes) that show stakeholder management, messy data judgment, and recovery from a wrong call. Map each story to a trait so you can redeploy it.
If your resume only says "analyzed healthcare data," rewrite the bullet to name the decision, the method, and the bounded result. The resume grader is useful for that pass.
Practice this before your phone screen
Run one candidate-led case today where you force yourself to ask for net price and for the diagnosis-to-treatment funnel before any revenue number. Use /start for a five-minute typed rep with instant scores (no account required), or a full voice case on /interview. Drill the funnel math on /drills/market-sizing and structure habits on /drills/structure. Everything on CoachNed is open for seven days with no card; then $120 for a recruiting season or $49 a month.
For sector context beyond IQVIA, read the life sciences consulting case interview guide. For more candidate-led reps in a generalist frame, the BCG case interview practice drills transfer cleanly to the driving style.
Frequently asked questions
How long is the IQVIA interview process?
Recruiting folklore usually puts the arc at roughly three to four weeks from first contact to decision, but offices and teams differ. Use the timeline in your invitation and recruiter messages; do not plan around a blog's schedule.
Are IQVIA case interviews candidate-led?
Yes in the consulting tracks that use live cases: you are expected to structure, request data, and recommend without being walked through exhibits. If you have only practiced interviewer-led formats, that driving habit is the main skill gap.
Do I need a science or pharmacy degree for IQVIA consulting?
No for many strategy and analytics roles, though life-sciences degrees appear often on team postings. You do need enough literacy to discuss phases, labels, payers, and net price without bluffing. Science depth without commercial sense fails the same way commercial sense without any domain language does.
What is the IQVIA written case?
Final rounds often include a timed packet and a short slide recommendation. Lead with the call, show the demand and access math, name risks, and list next steps. Confirm timing and slide count with your recruiter; published firm pages rarely specify a universal format.
How should I prepare differently than for McKinsey?
Keep the structured thinking. Drop the expectation that the interviewer will sequence exhibits for you. Add the patient-to-net-revenue funnel and practice saying "I need net price and covered lives" out loud until it is automatic.
Sources
- IQVIA Reports Fourth-Quarter and Full-Year 2025 Results — full-year 2025 revenue of $16.31 billion and segment context. Checked 2026-09-24.
- About IQVIA — ~93,000 employees, operations in 100+ countries, Connected Intelligence positioning. Checked 2026-09-24.
- Associate, Healthcare & Analytics Strategy Consulting (MASC) — market access problem framing, associate role responsibilities, and data-heavy consulting work. Checked 2026-09-24.
- The Drug Development Process (FDA) — official five-step overview from discovery through post-market monitoring. Checked 2026-09-24.
- Step 3: Clinical Research (FDA) — Phase 1–4 participant scale and purpose. Checked 2026-09-24.